Substance-related and addictive disorders

Last updated: November 2, 2023

Summarytoggle arrow icon

Substance-related disorders are a class of psychiatric disorders characterized by a craving for, the development of tolerance to, and difficulties in controlling the use of a particular substance or set of substances. There are two groups of substance-related disorders: substance-induced disorders and substance use disorders (SUDs). Substance-induced disorders include intoxication, withdrawal, and substance-induced mental disorders. SUDs (e.g., opioid use disorder and alcohol use disorder) have unique features but are all characterized by cognitive and behavioral changes and physical symptoms related to the continued use of one or more substances despite negative consequences. The addictive potential of these substances results from how they act on the brain's reward system and affect emotion, mood, and perception, often inducing a euphoric state colloquially referred to as a “high.” Individuals with SUD may participate in high-risk or illegal behaviors (e.g., exchanging sex for drugs, unsafe needle practice, erratic or aggressive behavior, theft), either as a result of substance use or in pursuit of substances, which can lead to social isolation, housing instability, and worsening of mental illness (e.g., comorbid bipolar disorder, major depressive disorder, or anxiety disorder). Treatment for SUD involves counseling (e.g., motivational interviewing), psychotherapy, and/or pharmacotherapy.

Classificationtoggle arrow icon

Definitiontoggle arrow icon

Substance use disorder [1][2][3]

  • Description: a chronic condition in which an uncontrolled pattern of substance use leads to significant physical, psychological, and social impairment or distress, with continued use despite substance-related problems.
  • Epidemiology
  • Characteristics: features that are typical for all substance use disorders (≥ 2 features must occur within 1 year to fulfill the DSM-V criteria)
    • Impaired control
      • Using a substance in larger amounts and/or for a longer time than originally intended
      • Repeated failed attempts to cut down on use
      • A great deal of time spent on substance-related activities (e.g., seeking out, buying, using, recovering from use)
      • Intense desire to obtain and use substance (craving)
    • Social impairment
      • Problems fulfilling work, school, family, or social obligations (e.g., not attending work or school, neglecting children or partner)
      • Problems with interpersonal relationships directly related to substance use (withdrawal from relationships, marital issues)
      • Reduced social, occupational, and recreational activities (e.g., less time socializing with friends, neglecting hobbies)
    • Risky use
      • Use in physically hazardous situations; (e.g., driving a car under the influence, unprotected sex, operating heavy machinery)
      • Continued use despite awareness of problems related to or exacerbated by substance use (e.g., continued alcohol use despite having cirrhosis)
    • Pharmacologic indicators
      • Drug tolerance: the need to continuously increase the dose of a substance to achieve the same desired effect
      • Drug withdrawal: a substance-dependent collection of symptoms that appear after cessation of prolonged heavy drug use accompanied by a strong urge to readminister the substance
  • Exception: patients undergoing supervised treatment with certain psychoactive substances (e.g., stimulants, cocaine, opioids, nitrous oxide, sedative-hypnotic drugs, anxiolytic drugs, cannabis) [4]
    • Tolerance and withdrawal can be normal physiological adaptations.
    • In the absence of other DSM-V criteria, tolerance and withdrawal do not necessarily indicate substance use disorder.

Withdrawal from some substances, such as alcohol, benzodiazepines, and barbiturates, can be fatal!

Substance-induced disorders

  • Intoxication: a temporary condition caused by recent ingestion of a substance that alters a person's consciousness, cognition, perception, judgment, affect, and/or behavior; commonly occurs in substance use disorders but also in one-off use
  • Withdrawal: a condition characterized by behavioral, physiological, and cognitive changes caused by a sudden reduction or cessation of substance intake after a prolonged period of heavy intake; usually occurs in association with substance use disorders
  • Substance/medication-induced mental disorders: a psychiatric disorder that develops within 1 month of intoxication or withdrawal of a substance and is not attributable to an independent mental disorder (e.g., substance/medication-induced anxiety disorder)

Related definitions

  • Abuse
    • In the context of substance use, the term “abuse” should generally be avoided due to its impreciseness and the historical burden of stigma.
    • “Substance use” is generally the preferred term in this context, with “substance misuse” being appropriate in the context of prescription drugs.
  • Drug-seeking behavior
    • A maladaptive behavioral response to substance addiction that involves manipulative and/or demanding behaviors to obtain the desired substance
    • Often indicative of an underlying substance use disorder
    • Examples of drug-seeking behavior
      • Faking/aggravating symptoms
      • Bribes, threats, theft (e.g., prescription pads)
      • Forging prescriptions or using those of others (e.g., under the names of family members)
      • Pretending to lose prescriptions and asking for new ones
      • Insisting that a treatment that does not involve one or more certain (addictive) drugs is ineffective or not tolerated (e.g., due to an alleged allergy)
      • Demanding a stronger medication or higher dose due to an allegedly high drug tolerance
      • Claiming that another, an ostensibly more experienced or more caring, physician would prescribe the desired drug or threatening to see another physician if the desired drug is not prescribed.
  • Medication-assisted treatment (MAT): treatment for substance use disorder that combines counseling with pharmacological and behavioral therapy, tailored to each patient's needs. [5]

Overviewtoggle arrow icon

Overview of substance intoxication and withdrawal [6]
Intoxication Withdrawal
Substance Pupils Cardiovascular system Concomitant symptoms


  • Normal (mild intoxication)
  • Mydriasis (severe intoxication)
  • ↓ Appetite, weight loss
  • ↑ Libido

Synthetic cathinones

  • Aggression, confusion
  • Muscle spasms
  • Euphoria
  • Restlessness, anxiety, insomnia
  • ↑ Gastrointestinal motility, weight loss
  • Conjunctival injection (red eyes)
  • ↑ Appetite, dry mouth
  • Impaired reaction time, concentration, and motor coordination
  • Social detachment
  • Irritability, anxiety, depression
  • ↓ Appetite, anorexia
  • Restlessness, sleep disturbances

Lysergic acid diethylamide (LSD)

  • Flashbacks (rarely unsettling)
  • None
  • Changes in sleep and appetite
  • Difficulty concentrating
  • Fatigue, depression, anxiety
Phencyclidine (PCP)
Gamma-hydroxybutyric acid (GHB) Low dose
  • Intensification of sensory experience
  • Enhanced empathy and libido
  • Disinhibition
High dose

Management of substance use disordertoggle arrow icon

SUD screening [8]


Validated screening tools

The harms of screening for unhealthy drug use outweigh the benefits when treatment cannot be provided or when findings may result in punitive actions (e.g., some US state laws penalize pregnant individuals who use substances or seek addiction treatment). [11]

SUD assessment [5]

The screening, brief intervention, and referral to treatment (SBIRT) model may be used to identify and assess SUD in any care setting. [5]

Drug testing [12][13]

  • Definition: the testing of biological samples for the presence of drugs and drug metabolites

Urine drug test

Urine drug test immunoassays can generate false-positive and false-negative results because of cross-reactivity with other medications (e.g., rifampin with opioid assays, sertraline with benzodiazepines, metformin with amphetamines). [12]

Blood/serum drug test

Laboratory methods

  • Immunoassays
  • Mass spectrometry
    • Often obtained based on a presumptive positive result
    • Definitive results
    • Can provide quantitative drug levels

Always confirm qualitative point-of-care drug test results (i.e., with mass spectrometry) when the results might have legal, financial, or employment implications.


Disposition [16][17]

The most appropriate treatment setting may change over time and is influenced by: [18]

Withdrawal management settings [16][17]

Setting Indications Description
  • Inpatient treatment program
  • Daily physician evaluations
  • Addiction services
  • Severe withdrawal
  • Need for 24-hour support
  • Outpatient withdrawal treatment is neither safe nor feasible.
  • Inpatient treatment program
  • Access to a physician
  • Addiction services
Intensive outpatient
  • Patients with:
    • Need for daily support
    • Reliable means to access care (e.g., transportation)
    • A supportive living environment
  • Outpatient programs in specialized centers
  • High patient oversight
  • Direct administration of medications (e.g., methadone)
  • Stable patients with:
    • Less than daily support needs
    • A secure living environment
    • High general functioning
  • Home or clinic setting
  • Lower patient oversight than intensive outpatient WM
  • Physicians prescribe medications for outpatient use.

Forced treatment is not recommended as it is often followed by relapse and a loss of trust in treatment services and providers.

Alcohol-related disorderstoggle arrow icon

See the article on alcohol-related disorders.

Caffeine-related disorderstoggle arrow icon

Cannabis-related disorderstoggle arrow icon

  • Cannabis use disorder: DSM-V requires ≥ 2 of the following features to occur within a 1-year period of cannabis use, accompanied by agitation and severe impairment of functioning
    • Using cannabis in larger amounts or over a longer period than intended
    • Persistent desire to cut down the amount of cannabis used or repeated unsuccessful efforts to stop using it
    • A large amount of time is spent using cannabis, trying to acquire it, or recovering from its effects
    • Strong craving to consume cannabis
    • Cannabis use has a negative impact on social and professional function (e.g., at work, school, or home)
    • Continued cannabis use despite social or interpersonal problems that are directly caused or exacerbated by its use
    • Loss of interest in activities that were important to user prior to regular cannabis use
    • Recurrent use of cannabis in situations in which its use is associated with the risk of physical harm (e.g., driving a car)
    • Continued cannabis use despite persistent or recurrent psychological or physical problems that can most likely be attributed directly to the use of cannabis
    • Tolerance, which can manifest as:
      • The need to markedly increase the amount of cannabis to achieve the desired effect/intoxication
      • A reduced effect over time when the same amount of cannabis is used
    • Withdrawal, which can manifest in the form of:
  • Other cannabis-induced disorders

Hallucinogen-related disorderstoggle arrow icon

Hallucinogens are a heterogeneous group of substances that can trigger hallucinations following exposure. These substances have varying mechanisms of action and associated physiological and neuropsychiatric effects.

Substances with hallucinogenic properties [23][24]

Commonly used substances include:

LSD, DMT, psilocybin, and MDMA are controlled substances in the United States. [23]

Classic hallucinogens may be beneficial for the treatment of depression and anxiety. [26]

Hallucinogen intoxication

Hallucinogen withdrawal

  • Hallucinogens are not typically associated with symptoms of withdrawal.
  • Withdrawal symptoms (e.g., cravings) may occur in chronic MDMA users; see “Stimulant withdrawal.” [27]

Hallucinogen persisting perception disorder (HPPD; flashbacks) [28]

  • Episodic or continuous symptoms (optical hallucinations, depression, and panic) that occur weeks after the initial intoxication
  • Spontaneous recurrence of acute hallucinogen intoxication due to reabsorption of the intoxicating substance from bodily stores

Phencyclidine use disordertoggle arrow icon

Other hallucinogen use disordertoggle arrow icon

LSD [6]

Phenethylamine derivatives

A class of substances with serotonergic and sympathomimetic effects

Inhalant-related disorderstoggle arrow icon

Opioid-related disorderstoggle arrow icon

See “Opioid use disorder“ for details.

Sedative, hypnotic, and anxiolytic related disorderstoggle arrow icon

Stimulant-related disorderstoggle arrow icon

See “Stimulant intoxication and withdrawal” for evaluation and management of acute intoxication and withdrawal of stimulant drugs.

Tobacco-related disorderstoggle arrow icon

  • Substance: nicotine from the tobacco plant (consumed in cigarettes, cigars, pipes, e-cigarettes)
  • Mechanism of action: stimulates nicotinic receptors in autonomic gangliasympathetic and parasympathetic stimulation [39]
  • Epidemiology [40]
    • Approx. 13% of adults in the US smoke cigarettes
    • Most prevalent cause of preventable morbidity and mortality in the US
  • Clinical features
  • Assessment: Smoking history is measured in pack years, which is used to quantify a person's lifetime exposure to tobacco.
    • The number of cigarette packs (20 cigarettes) that a person smokes per day multiplied by the number of years of cigarette consumption, e.g., (1 pack/day) x (10 years smoking history) = 10 pack years.
  • Treatment [39][41]
    • Counseling and support
    • Varenicline (alpha-4-beta-2 nACHR partial agonist): reduces positive symptoms and prevents withdrawal
    • Bupropion: reduces craving and withdrawal symptoms
    • Nicotine replacement therapy; (inhaler, lozenges; , transdermal patch; , nasal spray, gum)
  • Complications [39][41]

Gambling disordertoggle arrow icon

Gamma-hydroxybutyric acid usetoggle arrow icon

GHB is sometimes used as an acquaintance rape drug because it is hard to detect and has amnestic effects and a rapid onset of action.

Referencestoggle arrow icon

  1. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. American Psychiatric Association ; 2013
  2. dos Santos RG, Bouso JC, Rocha JM, Rossi GN, Hallak JE. The Use of Classic Hallucinogens/Psychedelics in a Therapeutic Context: Healthcare Policy Opportunities and Challenges. Risk Manag Healthc Policy. 2021; Volume 14: p.901-910.doi: 10.2147/rmhp.s300656 . | Open in Read by QxMD
  3. Morris H, Wallach J. From PCP to MXE: a comprehensive review of the non‐medical use of dissociative drugs. Drug Test Anal. 2014; 6 (7-8): p.614-632.doi: 10.1002/dta.1620 . | Open in Read by QxMD
  4. Nguyen L, Thomas KL, Lucke-Wold BP, Cavendish JZ, Crowe MS, Matsumoto RR. Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders. Pharmacol Ther. 2016; 159: p.1-22.doi: 10.1016/j.pharmthera.2016.01.016 . | Open in Read by QxMD
  5. Muttoni S, Ardissino M, John C. Classical psychedelics for the treatment of depression and anxiety: A systematic review. J Affect Disord. 2019; 258: p.11-24.doi: 10.1016/j.jad.2019.07.076 . | Open in Read by QxMD
  6. Barile FA. Barile's Clinical Toxicology. CRC Press ; 2019
  7. Meyer J. 3,4-methylenedioxymethamphetamine (MDMA): current perspectives. Subst Abuse Rehabil. 2013: p.83.doi: 10.2147/sar.s37258 . | Open in Read by QxMD
  8. Orsolini L, Papanti GD, De Berardis D, Guirguis A, Corkery JM, Schifano F. The “Endless Trip” among the NPS Users: Psychopathology and Psychopharmacology in the Hallucinogen-Persisting Perception Disorder. A Systematic Review. Frontiers in Psychiatry. 2017; 8.doi: 10.3389/fpsyt.2017.00240 . | Open in Read by QxMD
  9. Kampman KM. The treatment of cocaine use disorder. Sci Adv. 2019; 5 (10).doi: 10.1126/sciadv.aax1532 . | Open in Read by QxMD
  10. Courtney KE, Ray LA. Methamphetamine: An update on epidemiology, pharmacology, clinical phenomenology, and treatment literature. Drug Alcohol Depend. 2014; 143: p.11-21.doi: 10.1016/j.drugalcdep.2014.08.003 . | Open in Read by QxMD
  11. Heard K, Hoppe J. Phencyclidine (PCP) intoxication in adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. Last updated: April 9, 2018. Accessed: March 20, 2019.
  12. Walls R, Hockberger R, Gausche-Hill M. Rosen's Emergency Medicine. Elsevier Health Sciences ; 2018
  13. Dominici P, Kopec K, Manur R, Khalid A, Damiron K, Rowden A. Phencyclidine Intoxication Case Series Study. Journal of Medical Toxicology. 2014; 11 (3): p.321-325.doi: 10.1007/s13181-014-0453-9 . | Open in Read by QxMD
  14. Lande RG. Nicotine Addiction. In: Xiong GL, Nicotine Addiction. New York, NY: WebMD. Updated: August 10, 2017. Accessed: December 9, 2017.
  15. Current Cigarette Smoking Among Adults in the United States.,smokers%20want%20to%20quit%20smoking.. Updated: March 17, 2022. Accessed: May 24, 2022.
  16. Rigotti N. Overview of smoking cessation management in adults. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. Last updated: August 9, 2018. Accessed: March 20, 2019.
  17. Bates MLS, Trujillo KA. Use and abuse of dissociative and psychedelic drugs in adolescence. Pharmacol Biochem Behav. 2021; 203: p.173129.doi: 10.1016/j.pbb.2021.173129 . | Open in Read by QxMD
  18. Devlin RJ, Henry JA. Clinical review: Major consequences of illicit drug consumption. Critical Care. 2008; 12 (1): p.202.doi: 10.1186/cc6166 . | Open in Read by QxMD
  19. Uthaug MV, Davis AK, Haas TF, et al. The epidemiology of mescaline use: Pattern of use, motivations for consumption, and perceived consequences, benefits, and acute and enduring subjective effects. J Psychopharmacol. 2021; 36 (3): p.309-320.doi: 10.1177/02698811211013583 . | Open in Read by QxMD
  20. Dinis-Oliveira RJ, Pereira CL, da Silva DD. Pharmacokinetic and Pharmacodynamic Aspects of Peyote and Mescaline: Clinical and Forensic Repercussions. Curr Mol Pharmacol. 2019; 12 (3): p.184-194.doi: 10.2174/1874467211666181010154139 . | Open in Read by QxMD
  21. Jones AW, Holmgren A, Kugelberg FC. Driving under the influence of gamma-hydroxybutyrate (GHB). Forensic Science, Medicine, and Pathology. 2008; 4 (4): p.205-211.doi: 10.1007/s12024-008-9040-1 . | Open in Read by QxMD
  22. Teter CJ, Guthrie SK. A Comprehensive Review of MDMA and GHB: Two Common Club Drugs. Pharmacotherapy. 2001; 21 (12): p.1486-1513.doi: 10.1592/phco.21.20.1486.34472 . | Open in Read by QxMD
  23. Zvosec DL, Smith SW. Gamma Hydroxybutyrate (GHB) Intoxication. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. Last updated: March 8, 2017. Accessed: September 14, 2017.
  24. Zvosec DL, Smith SW. Gamma Hydroxybutyrate (GHB) Dependence and Withdrawal. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. Last updated: August 7, 2012. Accessed: September 14, 2017.
  25. Shapiro B, Coffa D, McCance-Katz EF. A primary care approach to substance misuse. Am Fam Physician. 2013; 88 (2): p.113-21.
  26. USPSTF, Krist AH, Davidson KW, et al. Interventions for Tobacco Smoking Cessation in Adults, Including Pregnant Persons: US Preventive Services Task Force Recommendation Statement. JAMA. 2021; 325 (3): p.265.doi: 10.1001/jama.2020.25019 . | Open in Read by QxMD
  27. USPSTF, Curry SJ, Krist AH, et al. Screening and Behavioral Counseling Interventions to Reduce Unhealthy Alcohol Use in Adolescents and Adults: US Preventive Services Task Force Recommendation Statement. JAMA. 2018; 320 (18): p.1899.doi: 10.1001/jama.2018.16789 . | Open in Read by QxMD
  28. USPSTF, Krist AH, Davidson KW, et al. Screening for Unhealthy Drug Use: US Preventive Services Task Force Recommendation Statement. JAMA. 2020; 323 (22): p.2301-2309.doi: 10.1001/jama.2020.8020 . | Open in Read by QxMD
  29. Miller SC, Fiellin DA, Rosenthal RN, Saitz R. The ASAM Principles of Addiction Medicine. LWW ; 2018
  30. Moeller KE, Kissack JC, Atayee RS, Lee KC. Clinical Interpretation of Urine Drug Tests: What Clinicians Need to Know About Urine Drug Screens. Mayo Clinic proc. 2017; 92 (5): p.774-796.doi: 10.1016/j.mayocp.2016.12.007 . | Open in Read by QxMD
  31. Jarvis M, Williams J, Hurford M, et al. Appropriate Use of Drug Testing in Clinical Addiction Medicine. J Addict Med. 2017; 11 (3): p.163-173.doi: 10.1097/adm.0000000000000323 . | Open in Read by QxMD
  32. Brahm NC, Yeager LL, et al. Commonly prescribed medications and potential false-positive urine drug screens. American Journal of Health-System Pharmacy. 2010; 67 (16): p.1344-1350.doi: 10.2146/ajhp090477 . | Open in Read by QxMD
  33. Ashford RD, Brown AM, McDaniel J, Curtis B. Biased labels: An experimental study of language and stigma among individuals in recovery and health professionals. Subst Use Misuse. 2019; 54 (8): p.1376-1384.doi: 10.1080/10826084.2019.1581221 . | Open in Read by QxMD
  34. Donroe JH, Holt SR, Tetrault JM. Caring for patients with opioid use disorder in the hospital.. CMAJ : Canadian Medical Association journal = journal de l'Association medicale canadienne. 2016; 188 (17-18): p.1232-1239.doi: 10.1503/cmaj.160290 . | Open in Read by QxMD
  35. Kosten TR, Baxter LE. Review article: Effective management of opioid withdrawal symptoms: A gateway to opioid dependence treatment. The American Journal on Addictions. 2019; 28 (2): p.55-62.doi: 10.1111/ajad.12862 . | Open in Read by QxMD
  36. Crotty K, Freedman KI, Kampman KM. Executive Summary of the Focused Update of the ASAM National Practice Guideline for the Treatment of Opioid Use Disorder. J Addict Med. 2020; 14 (2): p.99-112.doi: 10.1097/adm.0000000000000635 . | Open in Read by QxMD
  37. Perry H. Inhalant Abuse in Children and Adolescents. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. Last updated: October 27, 2017. Accessed: December 9, 2017.
  38. Domino FJ. Overview of Gambling Disorder. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. Last updated: July 14, 2017. Accessed: December 9, 2017.
  39. Slutske WS. Natural recovery and treatment-seeking in pathological gambling: Results of two U.S. national surveys. Am J Psychiatry. 2006; 163 (2): p.297-302.doi: 10.1176/appi.ajp.163.2.297 . | Open in Read by QxMD
  40. Murray A, Traylor J. Caffeine Toxicity. StatPearls. 2020.
  41. Willson C. The clinical toxicology of caffeine: A review and case study. Toxicology Reports. 2018; 5: p.1140-1152.doi: 10.1016/j.toxrep.2018.11.002 . | Open in Read by QxMD
  42. Bordeaux B, Lieberman HR. Benefits and Risks of Caffeine and Caffeinated Beverages. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. Last updated: October 11, 2017. Accessed: December 9, 2017.
  43. Yew D. Caffeine Toxicity. In: Miller MA, Caffeine Toxicity. New York, NY: WebMD. Updated: June 6, 2017. Accessed: December 9, 2017.
  44. Dugosh KL, Cacciola JS. Clinical Assessment of Substance Use Disorders. In: Post TW, ed. UpToDate. Waltham, MA: UpToDate. Last updated: April 18, 2017. Accessed: December 4, 2017.
  45. Krause RS. Alcohol and Substance Abuse Evaluation. In: Brenner BE, Alcohol and Substance Abuse Evaluation. New York, NY: WebMD. Updated: February 12, 2016. Accessed: December 4, 2017.
  46. Hasin DS, O’Brien CP, Auriacombe M, et al. DSM-5 Criteria for Substance Use Disorders: Recommendations and Rationale. Am J Psychiatry. 2013; 170 (8): p.834-851.doi: 10.1176/appi.ajp.2013.12060782 . | Open in Read by QxMD
  47. Overview of the Drug Overdose Epidemic: Behind the Numbers. Updated: December 19, 2018. Accessed: March 19, 2019.
  48. Campbell GA, Rosner MH. The Agony of Ecstasy: MDMA (3,4-Methylenedioxymethamphetamine) and the Kidney. Clin J Am Soc Nephrol. 2008; 3 (6): p.1852-1860.doi: 10.2215/cjn.02080508 . | Open in Read by QxMD
  49. Gershman and Fass. Synthetic cathinones ('bath salts'): legal and health care challenges.. P & T : a peer-reviewed journal for formulary management. 2012; 37 (10): p.571-95.
  50. Opioids portal. Updated: September 6, 2019. Accessed: October 28, 2019.

Icon of a lock3 free articles remaining

You have 3 free member-only articles left this month. Sign up and get unlimited access.
 Evidence-based content, created and peer-reviewed by physicians. Read the disclaimer